LT - Niraparibas, abiraterono acetatas ir prednizonas, skirti gydyti prostatos vėžį
EN - NIRAPARIB, ABIRATERONE ACETATE AND PREDNISONE FOR TREATING PROSTATE CANCER
Legal status
Patent in force
Bibliographic data
Indications of the International Patent Classification (IPC)
| (51) |
INT.CL. |
A61K 31/454 |
(2006.01) |
|
|
A61K 31/573 |
(2006.01) |
|
|
A61K 31/58 |
(2006.01) |
|
|
A61P 35/00 |
(2006.01) |
European patent
| (11) |
Number of the document |
3609497 |
| (13) |
Kind of document |
T |
| (96) |
European patent application number |
18720895.4 |
|
Date of filing the European patent application |
2018-04-09 |
| (97) |
Date of publication of the European application |
2020-02-19 |
| (45) |
Date of publication and mention of the grant of the patent |
2022-10-12
|
| (46) |
Date of publication of the claims translation |
2022-12-12
|
PCT application
| (86) |
Number |
PCT/US2018/026661 |
|
Date |
2018-04-09 |
PCT application publication
| (87) |
Number |
WO 2018/191141 |
|
Date |
2018-10-18 |
Priority applications
| (30) |
Number |
Date |
Country code |
|
201762485164 P |
2017-04-13
|
US |
Inventors
| (72) |
YU, Margaret K. , US
SNYDER, Linda Anne , US
|
Grantee
| (73) |
Janssen Pharmaceutica NV ,
Turnhoutseweg 30, 2340 Beerse,
BE
|
Attorney or representative
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
Title
| (54) |
Niraparibas, abiraterono acetatas ir prednizonas, skirti gydyti prostatos vėžį |
| |
NIRAPARIB, ABIRATERONE ACETATE AND PREDNISONE FOR TREATING PROSTATE CANCER |
Last renewal fee
|
Payment date |
Validity (years) |
Amount |
|
2025-03-05 |
8 |
185.00
EUR
|
Next renewal fee
|
2026-04-09 |
